相似文献
1
Discontinuation Syndrome With JAK2 Selective Agents: Case Presentation and Mechanistic Insights.
JCO Precis Oncol. 2024 Jan;8:e2300234. doi: 10.1200/PO.23.00234.
2
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818.
3
Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden.
Blood Adv. 2020 Dec 8;4(23):5929-5935. doi: 10.1182/bloodadvances.2020002970.
4
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis.
Future Oncol. 2025 Jul;21(16):2067-2075. doi: 10.1080/14796694.2025.2511562. Epub 2025 Jun 6.
5
A comprehensive review of pacritinib in myelofibrosis.
Future Oncol. 2015;11(20):2819-30. doi: 10.2217/fon.15.200. Epub 2015 Sep 14.
6
The role of pacritinib in the management of myelofibrosis.
Expert Rev Hematol. 2014 Jun;7(3):325-32. doi: 10.1586/17474086.2014.905200. Epub 2014 Apr 21.
7
The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
Expert Rev Anticancer Ther. 2016 Nov;16(11):1101-1108. doi: 10.1080/14737140.2016.1233061. Epub 2016 Sep 21.
8
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
Cochrane Database Syst Rev. 2015 Apr 10;2015(4):CD010298. doi: 10.1002/14651858.CD010298.pub2.
9
Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
PLoS One. 2019 Sep 27;14(9):e0222944. doi: 10.1371/journal.pone.0222944. eCollection 2019.
10
Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.
Cancer Lett. 2024 Aug 10;597:217023. doi: 10.1016/j.canlet.2024.217023. Epub 2024 Jun 7.
引用本文的文献
1
Fedratinib in 2025 and beyond: indications and future applications.
Blood Adv. 2025 Apr 22;9(8):1907-1915. doi: 10.1182/bloodadvances.2024015365.
本文引用的文献
1
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2022 Sep;20(9):1033-1062. doi: 10.6004/jnccn.2022.0046.
2
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.
Haematologica. 2022 Jul 1;107(7):1599-1607. doi: 10.3324/haematol.2021.279415.
3
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis.
Blood Cancer J. 2021 Jan 7;11(1):4. doi: 10.1038/s41408-020-00392-1.
4
Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.
Sci Adv. 2018 Nov 28;4(11):eaat3834. doi: 10.1126/sciadv.aat3834. eCollection 2018 Nov.
5
Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.
Oncotarget. 2018 Sep 7;9(70):33416-33439. doi: 10.18632/oncotarget.26058.
6
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
JAMA Oncol. 2018 May 1;4(5):652-659. doi: 10.1001/jamaoncol.2017.5818.
7
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
Lancet Haematol. 2017 Jul;4(7):e317-e324. doi: 10.1016/S2352-3026(17)30088-1. Epub 2017 Jun 8.
8
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.
J Exp Pharmacol. 2016 Aug 16;8:11-9. doi: 10.2147/JEP.S110702. eCollection 2016.
9
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
Haematologica. 2016 Jun;101(6):660-71. doi: 10.3324/haematol.2015.141283.
10
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
JAMA Oncol. 2015 Aug;1(5):643-51. doi: 10.1001/jamaoncol.2015.1590.
Zotero 插件